title: Evidence that zero antigen-matched cyclosporine-treated renal transplant recipients have graft survival equal to that of matched recipients. Reevaluation of points.
abstract: The value of HLA matching in cadaver renal transplantation (CRT) continues to be debated. It has recently been suggested that increased importance be given to HLA matching for the distribution of cadaver kidneys. Such a policy would add both delay and expense to CRT, which could be justified only by significantly improved results. The results of CRT in 252 cyclosporine treated adult patients transplanted at our institution from November 1984 to April 1989 were reviewed. Kidneys were initially transplanted into crossmatch-negative recipients based on waiting time, regardless of match. From October 1987, a points system, based on United Network for Organ Sharing (UNOS) criteria has been used. Eighty-four pts. with zero antigen match with their donors were compared with 168 pts. sharing 1-6 Ag. Actuarial graft and patient survival were determined by the cumulative life table method and compared using a log rank test. Our results indicated no statistically significant difference in graft survival because of better matching or mismatching. These findings are in keeping with our previously reported long-term results for non-CsA pts. Past predictions of improved graft survival based upon better matching at our institution have not fulfilled expectations, with the exception of 6 Ag matches. In conclusion, increased emphasis on HLA matching with fewer "points" for poorer matches does not appear justifiable.
authors.affiliation: Montefiore Medical Center/Albert Einstein College of Medicine, Bronx, New York 10467.
authors.forename: S M
authors.initials: SM
authors.lastname: Greenstein
authors.forename: R S
authors.initials: RS
authors.lastname: Schechner
authors.forename: P
authors.initials: P
authors.lastname: Louis
authors.forename: D
authors.initials: D
authors.lastname: Senitzer
authors.forename: A
authors.initials: A
authors.lastname: Matas
authors.forename: F J
authors.initials: FJ
authors.lastname: Veith
authors.forename: V A
authors.initials: VA
authors.lastname: Tellis
mesh_terms: D000328:Adult; D002102:Cadaver; D003524:Cyclosporins / Q000627:therapeutic use*; D006085:Graft Survival; D006680:HLA Antigens / Q000276:immunology*; D006648:Histocompatibility; D006801:Humans; D016030:Kidney Transplantation / Q000276:immunology*; D013997:Time Factors
chemical_list: D003524:Cyclosporins; D006680:HLA Antigens